Discriminatory roles for D1 and D2 dopamine receptor subtypes in the in vivo control of neostriatal cyclic GMP
- 1 May 1990
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 181 (1-2) , 17-21
- https://doi.org/10.1016/0014-2999(90)90240-7
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonistsNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1988
- Thienopyridine derivatives identified as the first selective, full efficacy, dopamine D1 receptor agonistsEuropean Journal of Pharmacology, 1987
- Modulation of In Vivo Dopamine Release by D2 but Not D1 Receptor Agonists and AntagonistsJournal of Neurochemistry, 1987
- Dopamine autoreceptor agonists including CGS 15855A decrease dopamine release and metabolism in mouse brainEuropean Journal of Pharmacology, 1987
- SCH-23390: A selective D1 dopamine antagonist with potent D2 behavioral actionsEuropean Journal of Pharmacology, 1984
- Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neurolepticsLife Sciences, 1984
- Protein Phosphorylation Catalyzed by Cyclic AMP-Dependent and Cyclic GMP-Dependent Protein KinasesAnnual Review of Pharmacology and Toxicology, 1980
- Multiple receptors for dopamineNature, 1979
- Effects of neuroleptics on 3H-haloperidol and 3H-CIS (Z)-flupenthixol binding and on adenylate cyclase activity in vitroLife Sciences, 1978
- Focussed microwave radiation: a technique to minimize post mortem changes of cyclic nucleotides, dopa and choline and to preserve brain morphologyNeuropharmacology, 1974